Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism

NCT00942968 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00942968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00942968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2009
Completion date
June 30, 2013
Enrollment
338 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

cancer